BioSpace News Archive

The Association for the Accreditation of Human Research Protection Programs today announced its first accreditations for 2019: a research institute in Massachusetts, a health care delivery system in California and a hospital in Taiwan.

OncLive®, the nation’s leading digital resource focused on providing oncology professionals with the most current and insightful information they need to provide the best patient care, will host its latest State of the Science Summit™ on ovarian cancer and soft tissue sarcoma Tuesday, March 26, from 5 to 9 p.m. at the Millennium Hilton New York in New York City.

The Medicrea Group (Euronext Growth Paris: FR0004178572-ALMED ; OTCQX Best Market –MRNTF), pioneering the transformation of spinal surgery through artificial Intelligence, predictive modeling and patient specific implants with its UNiD™ ASI (Adaptive Spine Intelligence) proprietary software platform, services and technologies, publishes its 2018 IFRS annual results,

ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets, today reported financial results for the quarter and full year ended 31 December 2018 and provided an update on its clinical activities.

“Health insurance helps individuals access the care they need, at the right time and in the right healthcare setting. That is essential to ensure better health for the people of New Jersey

ALZPROTECT, a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer’s disease, today announced that PAREXEL Biotech, a new division of PAREXEL International Corporation, has been selected to perform the clinical phase 2a development of AZP2006 for the treatment of PSP, a rare degenerative disease of the brain.

GB Sciences, Inc. (OTCQB: GBLX) today announced that The LSU Agricultural Center (AgCenter) received confirmation from the Louisiana Department of Agriculture and Forestry (LDAF) that GB Sciences Louisiana is deemed suitable for full-scale operations.

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of EXJADE®1 (deferasirox) Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, in the U.S.

Bally Ribbon Mills (BRM), an industry leader in the design, development, and manufacture of highly specialized engineered woven fabrics, highlights its line of biomedical tapes and webbing, ideal for use in cardiovascular, orthopedic, and dental prosthetic applications.

Applied LifeSciences & Systems announced the close of an $8 million Series A round of equity financing.